혈관신생에 대한 분자영상 = Molecular Imaging of Angiogenesis

다국어 초록 (Multilingual Abstract)

Angiogenesis, the process whereby new capillaries are formed by outgrowth from existing

microvessels, is required for tumor growth and metastasis, as well as for healing of ischemic

injuries. Because angiogenesis is a promising target for molecular therapies, there is a real need

to develop molecular imaging methods to monitor angiogenesis activity. Direct imaging of

angiogenesis can help define the pathophysiology of angiogenic processes in vivo, and foster

personized medicine by identifying patients likely to respond to angiogenesis-targeted drugs and

accurately monitor the therapeutic efficacy. Promising imaging targets include integrins, vascular

endothelial growth factor (VEGF) receptors, and matrix metalloproteinases. While MRI and

optical imaging modalities are also workable, radiolabeled RGD (arginine-glycine-aspartate)

probes that target αvβ3 integrins overexpressed on activated endothelia are the most extensively

investigated and successful angiogenesis imaging technique to date. This technique has

repeatedly been validated in preclinical models of cancers and ischemic diseases, and clinical

studies are presently ongoing to elucidate the value of RGD positron image tomography (PET)

imaging in human patients. Herein, we review the current status of angiogenesis imaging

research with special emphasis on integrin-targeted techniques.

참고문헌 (Reference)

1 Beer AJ, "[18F]galacto- RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck" 13 : 6610-6616, 2007

2 Bergers G, "Tumorigenesis and the angiogenic switch" 3 : 401-410, 2003

3 Ahn A, "Therapeutic angiogenesis: a new treatment approach for ischemic heart disease-part I" 16 : 163-171, 2008

4 Tongers J, "Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age" 118 : 9-16, 2008

5 Hwang R, "The role of integrins in tumor angiogenesis" 18 : 991-1006, 2004

6 Ferrara N, "The biology of VEGF and its receptors" 9 : 669-676, 2003

7 Lu E, "Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue" 108 : 97-103, 2003

8 Lee BC, "Synthesis of Tc-99m labeled glucosamino-Asp-cyclic (Arg- Gly-Asp-d-Phe-Lys) as a potential angiogenesis imaging agent" 15 : 7755-7764, 2007

9 Zhang C, "Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall super-paramagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner" 67 : 1555-1562, 2007

10 Riggs TL, "Research and development costs for drugs" 363 : 184-, 2004

11 Brooks PC, "Requirement of vascular integrin αvβ3 for angiogenesis" 264 : 569-571, 1994

12 Haubner R, "Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting" 40 : 1061-1071, 1999

13 Lee KH, "Radiolabeled RGD uptake and αv integrin expression is enhanced in ischemic murine hindlimbs" 46 : 472-478, 2005

14 Haubner R, "Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]galactoRGD" 2 : e70-, 2005

15 Haubner R, "Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glyco-peptide and positron emission tomography" 61 : 1781-1785, 2001

16 Meoli D, "Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction" 113 : 1684-1691, 2004

17 Hua J, "Noninvasive imaging of angiogenesis woth a 99mTc labeled peptide targeted at αvβ3 integrin after murine hindlimb ischemia" 111 : 3255-3260, 2005

18 Backer MV, "Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGFbased probes" 13 : 504-509, 2007

19 Li S, "Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma" 48 : 198-206, 2004

20 Makowski MR, "In vivo molecular imaging of angiogenesis, targeting alphavbeta3integrin expression, in a patient after acute myocardial infarction" 29 : 2201-, 2008

21 Pichler BJ, "Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD" 46 : 184-189, 2005

22 McDonald DM, "Imaging of angiogenesis: from microscope to clinic" 9 : 713-725, 2003

23 Provenzale JM, "Imaging of angiogenesis: clinical techniques and novel imaging methods" 188 : 11-23, 2007

24 Li S, "Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy" 14 : 1274-1277, 2003

25 Cai W, "How molecular imaging is speeding up antiangiogenic drug development" 5 : 2624-2633, 2006

26 Haubner R, "Glycosylated RGD- containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics" 42 : 326-336, 2001

27 Jung KH, "Favorable biokinetic and tumortargeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy" 47 : 2000-2007, 2006

28 Mulder WJ, "Early in vivo assessment of angiostatic therapy efficacy by molecular MRI" 21 : 378-383, 2007

29 Sipkins DA, "Detection of tumor angiogenesis in vivo by αvβ3 targeted magnetic resonance imaging" 4 : 623-626, 1998

30 Kerbel R, "Clinical translation of angiogenesis inhibitors" 2 : 727-739, 2002

31 Beer AJ, "Biodistribution and pharmacokinetics of the αvβ3 selective tracer 18F- galacto-RGD in cancer patients" 46 : 1333-1341, 2005

32 Carmeliet P, "Angiogenesis in health and disease" 9 : 653-660, 2003

33 Carmeliet P, "Angiogenesis in cancer and other diseases" 407 : 249-257, 2000

34 Ferrara N, "Angiogenesis as a therapeutic target" 438 : 967-974, 205